626

DRUG2 trials

Sponsors

Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.

Conditions

Healthy Subjects (HS)Systemic Lupus Erythematosus (SLE)

Phase 1

Evaluation of 626 in Healthy Adult Subjects

CompletedNCT06674525

Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.Healthy Subjects (HS)

Start: 2024-12-02End: 2025-08-28Updated: 2026-07-07

The Purpose of This Study is to Evaluate the Efficacy and Safety of 626 in the Treatment of SLE

RecruitingNCT07185269

Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.Systemic Lupus Erythematosus (SLE)

Start: 2025-09-24End: 2028-11-04Target: 198Updated: 2025-11-26